2seventy bio’s (TSVT) Sell (E+) Rating Reiterated at Weiss Ratings

Weiss Ratings reissued their sell (e+) rating on shares of 2seventy bio (NASDAQ:TSVT) in a research report sent to investors on Saturday morning,Weiss Ratings reports.

2seventy bio Price Performance

TSVT opened at $2.59 on Friday. 2seventy bio has a 12-month low of $2.35 and a 12-month high of $6.40. The stock has a market capitalization of $133.62 million, a PE ratio of -1.39 and a beta of 1.74. The firm’s fifty day moving average price is $3.02 and its 200 day moving average price is $4.02.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Erste Asset Management GmbH acquired a new stake in shares of 2seventy bio during the third quarter worth $25,000. Rhumbline Advisers raised its stake in 2seventy bio by 9.5% during the fourth quarter. Rhumbline Advisers now owns 84,670 shares of the company’s stock worth $249,000 after acquiring an additional 7,379 shares during the period. XTX Topco Ltd lifted its holdings in 2seventy bio by 61.1% in the third quarter. XTX Topco Ltd now owns 24,416 shares of the company’s stock worth $115,000 after acquiring an additional 9,257 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in 2seventy bio in the fourth quarter valued at approximately $32,000. Finally, Readystate Asset Management LP bought a new position in shares of 2seventy bio during the third quarter valued at approximately $53,000. Institutional investors and hedge funds own 93.90% of the company’s stock.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.